ReProtect  Products to protect reproductive health

About ReProtect
Contact ReProtect
Site Map

Phase II/III Clinical Trial for Contraceptive Efficacy

ReProtect, Inc.
November 2008

Two pivotal Phase II/III clinical trials of BufferGel® plus diaphragm as a contraceptive were recently completed in more than 1200 women, funded by the National Institutes of Health (NIH, NICHD Contraceptive Branch).

  • The first and larger trial was a randomized comparative study designed to test the non-inferiority of BufferGel to a marketed comparison spermicide, Gynol II, both products used with a diaphragm. The trial found BufferGel to be non-inferior to Gynol II; the point estimates of pregnancy rates were lower for BufferGel than for Gynol II.
  • The second, an open label trial, confirmed BufferGel’s effectiveness.

Thus, BufferGel with a diaphragm is a safe and effective contraceptive. The results of this trial are reported in: Barnhart et al, “Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: randomized controlled trial” Obstet Gynecol. 2007 Sep;110(3):577-86. .These successful trials represent a major milestone for ReProtect, and constitute the pivotal efficacy trials needed in preparation for New Drug Application (NDA) to the US FDA.


Back to Clinical Trials Index Page

Last updated 11/24/08  |  Legal Information  |  Copyright ReProtect Inc., 2003-2008